Gene Biotherapeutics Inc (CRXM) Return on Equity ROE from the fourth quarter 2020 to fourth quarter 2019 and annually, average high and low, overall ranking from Dec 31 2020 to Dec 31 2019 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Gene Biotherapeutics Inc   (CRXM)

Gene Biotherapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Gene Biotherapeutics Inc in the fourth quarter 2020?
Due to the lack of equity, it was not possible to calculate Gene Biotherapeutics Inc 's return on equity (ROE) in its fourth quarter 2020

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2020)
IV. Quarter		 (Sep 30 2020)
III. Quarter		 (Jun 30 2020)
II. Quarter		 (Mar 31 2020)
I. Quarter		 (Dec 31 2019)
IV. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -1 1 2 1 1
Return On Equity (TTM) - - - - -
CRXM's Total Ranking # # # # #
Equity (TTM) in Millions -5 -4 -4 -5 -5
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to CRXM Management Effectiveness >> CRXM's 5 Years Annual ROE >> Compare CRXM ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





CRXM Annual Return On Equity (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2016)
2016		 (Dec 31 2015)
2015		 (Dec 31 2014)
2014
Total Equity in Millions -5 -5 -3 -4 -2
Y / Y Equity Change - - - - -
Net Income in Millions -1 1 -3 -4 -6
Y / Y Net Income Change - - - - -
Return On Equity - - - - -

Back to CRXM Management Effectiveness >> CRXM's 5 Years Annual ROE >> Compare CRXM ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CRXM's' Return on Equity at Yahoo Finance
CRXM's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CRXM's Competitors
Subscribers only: Roe for Gene Biotherapeutics Inc 's Suppliers
Subscribers only: Return On Equity for CRXM's Customers




Companies with similar Return On Equity at Dec 31 2020, within Healthcare Sector ROE
Chemed Corporation  40.74 %
Zomedica Corp   39.66 %
Dexcom Inc   36.98 %
Lifevantage Corp  36.36 %
Pro dex Inc   36.16 %
Biogen Inc   35.89 %
Progyny Inc   35.26 %
Vertex Pharmaceuticals Inc  35.21 %
Purple Biotech Ltd  35.20 %
Bionexus Gene Lab Corp   34.37 %
Regeneron Pharmaceuticals Inc   33.19 %
Lakeland Industries Inc   32.69 %
Blueprint Medicines Corporation  30.97 %
Voyager Therapeutics Inc   30.80 %
Select Medical Holdings Corp  29.84 %
Pacira Biosciences inc   29.60 %
Inmode Ltd   29.37 %
Meridian Bioscience Inc   29.09 %
Resmed Inc   28.15 %
Biodelivery Sciences International Inc   28.14 %
Prestige Consumer Healthcare Inc   27.23 %
Glucotrack Inc   26.76 %
Seagen Inc   26.32 %
Organogenesis Holdings Inc   26.08 %
Xoma Royalty Corporation  26.08 %
Merck and Co Inc   26.06 %
Amedisys Inc  24.93 %
Emergent Biosolutions Inc   24.54 %
Quest Diagnostics Inc  24.14 %
Magellan Health inc   23.81 %

Date modified: 2026-09-08T15:10:34+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.